Citigroup Upgrades Bio-Rad Laboratories (NYSE:BIO) to Buy
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) was upgraded by stock analysts at Citigroup from a “neutral” rating to a “buy” rating in a report released on Tuesday, MarketBeat reports. The firm presently has a $400.00 price objective on the medical research company’s stock, up from their prior price objective of $350.00. Citigroup’s price target […]
3 Oct 08:28 · The Markets Daily